Your browser doesn't support javascript.
Efficacy and impact of SARS-CoV-2 vaccination on cancer treatment for breast cancer patients: a multi-center prospective observational study.
Terada, Mitsuo; Kondo, Naoto; Wanifuchi-Endo, Yumi; Fujita, Takashi; Asano, Tomoko; Hisada, Tomoka; Uemoto, Yasuaki; Yamanaka, Natsumi; Sugiura, Hiroshi; Mita, Keiko; Wada, Asaka; Takahashi, Eriko; Saito, Kanako; Yoshioka, Ryo; Toyama, Tatsuya.
  • Terada M; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Kondo N; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Wanifuchi-Endo Y; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Fujita T; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Asano T; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Hisada T; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Uemoto Y; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Akiko Kato; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Yamanaka N; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan.
  • Sugiura H; Departments of Breast and Endocrine Surgery, Nagoya City University West Medical Center, 1-1-1 Hirate-cho, Kita-ku, Nagoya, Aichi, 462-8508, Japan.
  • Mita K; Departments of Breast and Endocrine Surgery, Nagoya City University East Medical Center, 1-2-23 Wakamizu, Chikusa-ku, Nagoya, Aichi, 464-8547, Japan.
  • Wada A; Department of Surgery, Surgical Oncology and Science, Sapporo Medical University, S1W16, Chuoh-ku, Sapporo, Hokkaido, 060-8543, Japan.
  • Takahashi E; Department of Breast and Endocrine Surgery, Akita University Hospital, 1-1-1 Hondo, Akita, 010-8543, Japan.
  • Saito K; Department of Hematology and Oncology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.
  • Yoshioka R; Department of General Thoracic Surgery and Breast and Endocrine Surgery, Okayama University Graduate School of Medicine, 2-5-1 Shikata-cho, Kita-ku, Okayama, 700-8558, Japan.
  • Toyama T; Departments of Breast Surgery, Nagoya City University Graduate School of Medical Sciences, 1 Kawasumi, Mizuho-cho, Mizuho-ku, Nagoya, Aichi, 467-8601, Japan. t.toyama@med.nagoya-cu.ac.jp.
Breast Cancer Res Treat ; 195(3): 311-323, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2059914
ABSTRACT

PURPOSE:

Vaccination is an essential strategy to prevent infection in the SARS-CoV-2 pandemic. However, there are concerns about vaccine efficacy and the impact of vaccination on cancer treatment. Additionally, the emergence of novel variants may affect vaccination efficacy. This multi-center, prospective, observational study investigated the efficacy and impact of vaccination against SARS-CoV-2 variants on treatment among breast cancer patients in Japan.

METHODS:

Patients with breast cancer scheduled to be vaccinated with the SARS-CoV-2 vaccine from May to November 2021 were prospectively enrolled (UMIN000045527). They were stratified into five groups according to their cancer treatment no treatment, hormone therapy, anti-human epidermal growth factor receptor (HER)2 therapy, chemotherapy, and cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. Serum samples for assessing serological responses were collected before the first vaccination and after the second vaccination.

RESULTS:

Eighty-five breast cancer patients were included. The overall seroconversion rate after second vaccination was 95.3% and the lowest seroconversion rate was 81.8% in the patients under chemotherapy. The overall positivity rate of neutralizing antibodies against the wild-type, α, Δ, κ, and omicron variants were 90.2%, 81.7%, 96.3%, 84.1%, and 8.5%, respectively. Among the patients under chemotherapy or CDK4/6 inhibitors, various degrees of decreased neutralizing antibody titers against SARS-CoV-2 variants were observed. Withdrawal or reduction of systemic therapy because of vaccination was observed in only one patient.

CONCLUSION:

Our data support SARS-CoV-2 vaccination for breast cancer patients. However, a reduction in neutralizing antibody titers was suggested during chemotherapy and CDK4/6 inhibitors, raising concerns about the impact on long-term infection prevention.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / Viral Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Female / Humans Language: English Journal: Breast Cancer Res Treat Year: 2022 Document Type: Article Affiliation country: S10549-022-06693-2

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Breast Neoplasms / Viral Vaccines / COVID-19 Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Vaccines / Variants Limits: Female / Humans Language: English Journal: Breast Cancer Res Treat Year: 2022 Document Type: Article Affiliation country: S10549-022-06693-2